

**Audrey's Life Science Meeting Picks for March 26, 2017 – June 2017**  
**Complimentary Service of AudreysNetwork.com**  
**March 26, 2017**

\*\*\*\*\*

**Bio2Device Group, Tuesday Morning, March 28, 2017**

Topic: "BioNews and Open Forum Discussions"

Speaker: Harry Wachob, President & Founder of B2DG

Date and Time: Tuesday, March 28, 2017, 8:30 am

Location: Sunnyvale City Council Chambers- 456 West Olive Ave., Sunnyvale

There is no registration or fees for morning meetings.

**Speaker Bio**

Harry Wachob is the Founder and President of the Bio2Device Group. He is an experienced engineering leader in materials science, biomedical device engineering and R&D. He has directed and mentored multidisciplinary teams in solving complex technical issues in order to improve the safety, reliability, and performance of medical devices. Most recently, he was the Managing Materials Scientist at Xoft. Previously he was Director of Engineering for Aerogen, a biopharmaceutical company specializing in novel aerosol drug delivery. Prior to that, Harry was Managing Engineer at Exponent/Failure Analysis Associates where he guided research and development, and product failure investigations covering a broad range of medical and industrial applications. He received his BS, MS and PhD engineering degrees in Materials Science & Engineering from Cornell University.

Please join us for a roundup of the news from the last two weeks. This will be followed by Open Discussions and Networking

\*\*\*\*\*

**JLABS, Tuesday Morning, March 28, 2017**

Topic: "Meet with ...MPM Capital "Program Overview:

Speakers: Vinay Bhaskar, Ph.D., Principal with MPM Capital;

Luke Evnin | Managing Director, MPM Capital

Date and Time: Tuesday, March 28, 2017, 10:30 am

Agenda:

10:30am | Registration & Networking

11:00am | Presentation and Q&A

11:45am | Lunch & Networking

12:30-5:00pm | One-on-one Meetings\*

\*Companies must have applied for a one-on-one meeting ahead of time and been approved. Applications are due February 28. [Apply Here.](#)

Location: JLABS @ SSF, 329 Oyster Point Blvd - 3rd Floor, South San Francisco,

Fees:

Presentation

\$25 | General Public

\$35 | Onsite

Includes presentation, Q&A, and lunch. All attendees must pay this fee, regardless of one-on-one meeting status. Pre-registration to attend the presentation, Q&A, and lunch will remain open until March 28th (or sold out).

One-on-One Meeting

FREE | Application

FREE | Accepted Companies

Companies must have applied for a one-on-one meeting ahead of time. The one-on-one application period will close on February 28, 2017. Your application will be reviewed and you will be notified of acceptance by March 15, 2017. Acceptance of a one-on-one meeting is not guaranteed as all applications must be approved. Registration at <https://www.eventbrite.com/e/meet-with-mpm-capital-tickets-29590468889?aff=weekly>

#### Topic Description

Do you have innovation that will change the face of medicine? MPM Capital is looking for leading scientific research that addresses unmet medical needs across all therapeutic areas. MPM is no stranger to Johnson and Johnson Innovation, JLABS (JLABS) with investments that recently helped 3 Bay Area JLABS companies reach the next level. MPM is now investing two funds, BV2014, a \$400M fund focusing on early stage companies developing therapies for unmet medical needs (Series A and earlier), and the Oncology Impact Fund, a \$470M fund that invests solely in oncology companies of any stage (therapeutics only – no diagnostics). For more information on MPM visit <http://www.mpmcapital.com/>

Vinay Bhaskar, Ph.D., Principal with MPM Capital, will be in attendance to provide an overview presentation on MPM's key areas of interest and venture investment philosophy. Vin will be joined by Luke Evin to answer any questions and meet with a handful of applicants for one-on-one meetings. To be considered for a one-on-one meeting complete the information required in the link below.

#### About the Meet with... Series:

The purpose of the Meet with Series events sponsored by JLABS is to help start-up entrepreneurs, as well as the academic community, connect with potential partners, such as big pharma or other investment corporations, through one-on-one meetings. It is also a chance for the featured corporation to outline their specific business development goals and clarify what types of products or research they are interested in and how best to approach them to get the partnering process started. Past participants include the Wellcome Trust, Bill & Melinda Gates Foundation, MedImmune Ventures, Mercury Fund, DARPA's Biological Technologies Office, Correlation Ventures, Breakout Labs, New Enterprise Associates, Canaan Partners, Thomas McNerney & Partners, NCI, NCATS, NINDS, Allegory Venture Partners, Clarus Ventures, Johnson & Johnson Innovation, California Institute for Regenerative Medicine, Astellas Venture Management, and OrbiMed.

Do you have innovation that will change the face of medicine? MPM Capital is looking for leading scientific research that addresses unmet medical needs across all therapeutic areas.

#### Speaker Bios

Luke Evin, Ph.D., co-founded MPM with Ansbert Gadick in 1997 and opened the San Francisco office in 1999. The MPM team they have led has been the inspiration and driving force behind building companies such as Biomarin (BMRN), CoStim Pharmaceuticals (acquired by Novartis: NVS), Epizyme (EPZM), Idenix (acquired by Merck: MRK), Pacira (PCRX), Pharmasset (acquired by Gilead: GILD) and Radisu (RDUS). MPM believes that these companies are among the biggest successes in biotech history - companies that ultimately resulted in helping thousands of patients live longer with vastly improved lives. Luke was lead investor and has served on the boards of several of MPM's most successful investments including CoStim Pharmaceuticals, Idun Pharmaceuticals, and Pacira.

Prior to co-founding MPM, Luke honed his skills as a venture capitalist beginning in 1990 at Accel Partners where he focused on emerging healthcare companies. Luke's passion for drug discovery began in college where he received his A.B. in Molecular Biology from Princeton University. He advanced his technical training and launched his interest in curing disease with his doctoral study in Department of Biochemistry at the University of California - San Francisco. Luke's passion for discovering and pushing forward groundbreaking drug discovery companies inspires his work and that of his team. Luke has devoted significant efforts since 2000 to working with Scleroderma Research Foundation, serving as Chairman since 2002. Luke also devotes energy to the External Advisory Board at the Lewis-Sigler Institute for Quantitative Genomics at Princeton, serves on the External Advisory Boards for QB3 at UCSF, the Masters in Translation Medicine program at UCSF, and Boston University Scleroderma CORT.

Vinay Bhaskar, Ph.D., joined MPM in 2016 after leading External R&D for the Oncology therapeutic area at Amgen. In this role, Vin was instrumental in forging collaborations with companies such as Kite Pharma, Merck, and Xencor. During this time he also led internal immuno-oncology strategy discussions and served as executive sponsor and/or board observer for several Amgen Ventures investments, including Surface Oncology, Precision BioSciences and Tizona Therapeutics, a company founded by MPM. Vin joined Amgen through its acquisition of Onyx Pharmaceuticals, where he led preclinical search, evaluation, and diligence for licensing and acquisition opportunities on the Asset Acquisition Team. Prior to joining Onyx, Vin held a variety of roles of increasing responsibility in Discovery Research at Portola Pharmaceuticals, XOMA, PDL Biopharma and Eos Biotechnology. In these roles, he initiated and led multiple preclinical project teams and functional groups focused on biologics and spanned oncology, inflammation and cardio metabolic disease. Through these endeavors, Vin has gained broad expertise across all phases of drug discovery, early development and process sciences. Vin holds a Ph. D. in Biochemistry from UCLA and a B.S. in Biochemistry from UC Davis.

\*\*\*\*\*

**Palo Alto AWIS, Tuesday Evening, March 28, 2017**

Topic: "Public Policy and Government Careers for Scientists"

Date and Time: Tuesday, March 28, 2017, 7- 9 PM

7:00-7:30: Networking dinner

7:30-7:45: Announcements

7:45-9:00: Workshop

Location: PARC Auditorium, 3333 Coyote Hill Rd, Palo Alto, CA 94304, USA

Fee: free for members, \$15 for nonmember

Register at <http://www.brownpapertickets.com/event/2884603>

**Program Description**

Are you interested in tackling complex, multi-faceted problems at the interface between science and policy?

A career in policy-making and public service offers the opportunity to be the conduit between the worlds of science and policy. To learn more about what a career in public policy and government involves, join us for an interactive session with Erika Bustamante, Director of State Government Relations at Stanford University, and Rebecca Newhouse, Environmental Scientist at the US EPA.

**Speaker Bios**

Erika Bustamante manages the activities and relationships with state governmental bodies related to regulatory and legislative issues impacting Stanford's mission. Previous to joining Stanford, Bustamante worked as the Legislative Director for Assembly Member Luis Alejo. She is also a former California Science and Technology Policy Fellow. Bustamante holds a BS in Molecular, Cell and Developmental Biology from UCLA and a Ph.D. in Developmental Biology from Stanford University.

Rebecca Newhouse is an Environmental Scientist in the Air Division at US EPA, Region 9. Before joining the EPA, Rebecca worked as a committee consultant for the California State Senate Environmental Quality Committee. Prior to working for the State Legislature, she was a 2011/12 Science and Technology Policy Fellow with the California Council on Science and Technology. Rebecca has a PhD from UC Santa Cruz in chemistry and a bachelor's degree in biochemistry from Western Washington University in Bellingham.

\*\*\*\*\*

**Biomedical Engineering Society, Wednesday, March 29, 2017**

Event: 8th Annual Bay Area Biomedical Device Conference-Medical Devices in the Connected World

Date and Time: Wednesday, March 29, 2017, 7:30 am

Location: SJSU Student Union Ballroom, San Jose State University

Please take advantage of the reduced early registration which ends on March 16, 2017 at 5:00 pm. PST.

Visit our website at [www.biomedconference.org](http://www.biomedconference.org) for more details or email [info@biomedconference.org](mailto:info@biomedconference.org) if you have any questions.

Register at <http://www.biomedconference.org/register>

Event Description

The Biomedical Engineering Society at San Jose State University (SJSU) is happy to announce the 8th Annual Bay Area Biomedical Device Conference!

Some exciting features of this conference include:

- An expert biomedical plenary speaker
- Informative parallel sessions
- Interactive Industry & CEO Panels
- Student Research Posters
- Sponsors and representatives from various biomedical companies
- Wine & cheese networking reception
- & More!

\*\*\*\*\*

**Bioscience Forum, Wednesday Evening, March 29, 2017**

Topic: "Leveraging Biotech's Novel Platforms to Tackle Global Health: A Unique Business Model to Overcome Financial Barriers"

Speaker: Eric Easom, Vice President Neglected Disease R&D, Anacor Pharmaceuticals (Acquired by Pfizer June, 2016)

Date and Time: Wednesday, March 29, 2017, 6:00 PM - 9:00 PM

6 pm - 7 pm networking

7 pm - 8 pm dinner

8 pm - 9 pm presentation

Location: The Holiday Inn, 275 S Airport Blvd, South San Francisco, California 94080, USA

Join us from 6-9 pm to network and hear the latest scientific and business advances in the San Francisco Bay Area biotech community

Event Registration (\$3 service fee will apply)

Pre-Registration

\$50.00

On-Site Registration

\$60.00

Pre-Registration ends Monday, March 27th, at 9 pm

Cash or check accepted on the day of the event

\$10 discount for full-time students

Register at <http://biosf.org/>

Or you can pay with a check made out to "BioScience Forum" and sent to:

BioScience Forum

1442A Walnut Street, #308

Berkeley, CA 94709-1405

Please do not mail checks later than Thursday, March 23rd

If paying with check, do not complete online registration with Cvent

#### Topic Description

The world's poorest populations are disproportionately affected by neglected diseases, such as tuberculosis (TB), malaria, visceral leishmaniasis, Chagas disease, human African trypanosomiasis (sleeping sickness), and filarial worms. The current standards of care are difficult to administer, often have significant toxicities, and are increasingly becoming less effective due to the development of resistance. Despite the fact that these diseases cause significant morbidity and mortality worldwide, there has been little investment by industry in developing new therapies due to expectations of low financial returns.

In early disease screenings, Anacor's boron chemistry platform proved to be particularly well-suited for developing treatments for these types of infectious diseases. Though the company felt a responsibility to apply its technology to neglected disease R&D, it was venture-backed and pre-revenue. Devoting time and money to the pursuit of new therapies for complex, unprofitable global health markets could create a conflict with the objectives of its investors. To overcome this, Anacor devised a business plan to leverage non-dilutive funding sources to underwrite this important work. Over the past 10 years, this business model has funded the development of one of the most promising pipelines in this space, with two clinical candidates for African sleeping sickness and TB and the potential for five or more in the next 1-2 years. Over \$50 million of funding to subsidize this R&D was raised from non-profits, government agencies, companies and foundations such as the Bill & Melinda Gates Foundation and the Wellcome Trust. Anacor's drug discovery capabilities were supplemented with more than 50 external collaborators from academia, nonprofits and pharmaceutical partners that provided additional expertise in infectious disease biology. Eric will be sharing the story of Anacor's science, its business model, and the strategic value that can be gained from pursuing R&D programs in neglected diseases. The hope is to inspire others by example and demonstrate the depth of potential to treat some of the world's most devastating infectious diseases.

#### Speaker Bio

Eric is the Vice President for the Neglected Diseases Initiative at Anacor Pharmaceuticals Inc., overseeing the company's research and development efforts to

advance new therapeutics for the treatment of neglected diseases. He brings 26 years of pharmaceutical and biotech experience from various leadership roles in R&D program and alliance management, business development, marketing, sales, finance, and manufacturing from his time at Eli Lilly and Company, MedImmune, McKesson, and InteKrin Therapeutics.

Eric Easom served as a member of the Board of Directors at the Infectious Disease Research Institute (IDRI) from 2007-2014 and as Chairman from 2010-2013.

Eric received an MBA from Indiana University and a BS and Masters of Engineering from the University of Louisville.

\*\*\*\*\*

**San Jose State Biomedical Engineering Society, Wednesday, March 29, 2017**

Event: "8th Annual Bay Area Biomedical Device Conference-Medical Devices in the Connected World"

Date and Time: Wednesday, March 29, 2017, 7:30 am

Location: SJSU Student Union Ballroom, San Jose State University

Please take advantage of the reduced early registration which ends on March 16, 2017 at 5:00 pm. PST.

Conference Description

Some exciting features of this conference include:

- An expert biomedical plenary speaker
- Informative parallel sessions
- Interactive Industry & CEO Panels
- Student Research Posters
- Sponsors and representatives from various biomedical companies
- Wine & cheese networking reception
- & More!

Visit our website at [www.biomedconference.org](http://www.biomedconference.org) for more details or email [info@biomedconference.org](mailto:info@biomedconference.org) if you have any questions.

\*\*\*\*\*

**PBSS Workshop, Thursday Afternoon, March 30 2017**

Event: "Best CMC Practices for Successful Drug Development and Commercialization: Leveraging QbD and risk-based strategies for efficient CMC development"

Speakers: Prabu Nambiar, Edward Ciolkowski, James Bush (Syner-G Pharma Consulting)

Date and Time: Thursday, March 30, 2017, 12:30-5:00 pm Registration fee (US\$): Regular: \$125; Academic: \$75; For unemployed & students: \$25; For vendor-show reps: \$25; For major-sponsor rep (incl lunch): \$0; For others, details available upon online login.

Location: SF Bay Area: Foster City Crowne Plaza

Registration: <http://www.pbss.org/asp/eventInfo.aspx?eID=528>

Further Information:

Registration deadline: 3/28/2017 (it will close sooner if the seating cap is reached)

[support@PBSS.org](mailto:support@PBSS.org)

[www.PBSS.org](http://www.PBSS.org)

\*\*\*\*\*

**AWIS NCC Workshop, Saturday, April 1, 2017**

Workshop: "Leadership by Design: Using Design Thinking to transform your Career"

Workshop Leader: Christopher Ireland

Date and Time: Saturday, April 1<sup>st</sup>, 8:30am-2:00pm

8:30-9:00 Check in and breakfast  
9:00-9:15 Opening remarks  
9:15-12:00 Leadership by Design  
12:00-12:45 Networking lunch  
12:45-1:45 Leadership Panel  
1:45-2:00 Closing remarks

Location: Genentech, Inc. ([View](#)), Room B31-1A, 310 DNA Way, South San Francisco, CA 94080

Registration

<http://ebawis.us11.list-manage.com/track/click?u=0bfd730afa47c08495b877f1b&id=2dd81fdafe&e=e5488d3ca3>

Sign up for the workshop today!

Fees:

Register for tickets now for a reduced price (\$35 for members, \$50 for non-members).

<http://ebawis.us11.list-manage1.com/track/click?u=0bfd730afa47c08495b877f1b&id=90c3499acb&e=e5488d3ca3>

#### Workshop Description

Do you want to become a successful leader in a fast-paced and rapidly changing work environment? Join us for an interactive workshop on Design Thinking with Christopher Ireland, the coauthor of "Rise of the DEO". Here you will learn a unique perspective on leadership and gain the innovative strategies and skills you need to unleash your inner leader.

#### Leader Bio

Christopher Ireland worked for 20 years growing and developing Cheskin, a consultancy focused on product and market design innovation. Under her leadership as CEO, the company expanded into global markets, opened four offices, completed two successful mergers and gained a reputation for top quality performance serving a range of high growth clients including Microsoft, Intel, HP, Motorola, Pepsi and more. Christopher and her partners successfully sold Cheskin late in 2007.

Ms. Ireland has an M.B.A. from the Andersen School of Management (UCLA). She currently teaches graduate design students at California College of the Arts in San Francisco and Continuing Studies students at Stanford University. In 2013, she co-authored Rise of the DEO, (New Riders Press) a book examining contemporary leadership traits. She has lectured extensively on the topics of design, human behavior and corporate leadership.

\*\*\*\*\*

#### **QB3, Monday MidDay, April 3, 2017**

Topic: "How Federal Politics Impact Funding for Science and Startups"

Speaker: Ryan Davison, government affairs manager at the American Chemical Society in Washington, DC

Date and Time: Monday, April 3, noon to 1:00 pm

Location: Room N-114, Genentech Hall, UCSF Mission Bay

Fee: \$10 general admission

Register at [https://www.eventbrite.com/e/qb3-seminar-ryan-davison-ac-s-how-federal-politics-impact-funding-for-science-and-startups-tickets-32633279016?mc\\_cid=84bb71f0fb&mc\\_eid=cb4c38a44a](https://www.eventbrite.com/e/qb3-seminar-ryan-davison-ac-s-how-federal-politics-impact-funding-for-science-and-startups-tickets-32633279016?mc_cid=84bb71f0fb&mc_eid=cb4c38a44a)

#### Topic Description

Washington politics usually seem far removed from life at the lab bench. But issues at the federal level can affect what funds the government makes available for grants of all types, from R01 to SBIR. If you understand the ever-changing landscape, you may be able frame your application so it is successful, or expand into research areas that are more likely to get funded. To get the big picture from Ryan Davison, government affairs manager at the American Chemical Society in Washington, DC, join us on April 3. Ryan will provide a general political update, highlight specific pieces of legislation meaningful to researchers, discuss key congressional committees, and explain how Republicans and Democrats view the economy differently. Additionally, Ryan will take a look at SBIR and proof-of-concept funding, and highlight areas likely to get funding in the near future.

#### Speaker Bio

Dr. Ryan Davison is currently the Manager of Government Affairs at the American Chemical Society where he advocates for legislation that supports the chemical industry. Dr. Davison manages advocacy and policy development on priority issues including manufacturing, tax and trade, intellectual property, patents, biomedical research, innovation and competitiveness, agency funding, and appropriations. Most of his time is spent on Capitol Hill meeting with lawmakers and their staff, attending Congressional hearings and mark-ups, and monitoring bills relevant to the chemical enterprise. Ryan possesses a distinct background of policy and science experience. Before joining the ACS he worked as a policy Fellow at the National Academy of Sciences, served as Biosecurity Analyst at the Federation of American Scientists, was a post-doctoral Fellow at Georgetown University, and an adjunct professor at George Washington University. He holds a Bachelor's and Master's degree in Psychology from Appalachian State University, a Ph.D. in Neuroscience from the University of Alabama at Birmingham (UAB), and is in a unique position to be able to personally highlight the importance of innovation and research to members of Congress and their staff.

\*\*\*\*\*

#### **JLABS, Thursday, April 6, 2017**

Event: MedTech Innovator 2017: JLABS Pitch Event

Date and Time: Thursday, April 6, 2017, 9:00 am – 5:00 pm

Agenda:

9:00am - 9:30am | Registration Opens and Networking

9:30am - 10:00am | Welcome & Introduction

10:00am - 12:30pm | Pitch Session (4 companies)

12:30-1:30pm | Networking Lunch

1:30pm - 4:00pm | Pitch Session II (4 companies)

4:00pm - 4:30pm | Success Stories Feature

4:30pm - 5:00pm | Award Presentation

\*Companies must have applied to pitch ahead of time and be approved. The application deadline is Feb 28.

Location: JLABS @ SSF, 329 Oyster Point Blvd., Floor 3, South San Francisco, CA 94080

Fees: Free

\*Companies must have applied to pitch ahead of time and be approved. The application deadline is Feb 28.

Apply Now to Pitch at JLABS

The MedTech Innovator SF Pitch Event is open to all attendees. Startups interested in pitching are encouraged to apply at <http://medtechinnovator.org/apply>.

See details at <https://www.eventbrite.com/e/medtech-innovator-2017-jlabs-pitch-event-tickets-31169197910?aff=weekly>

#### Event Description

##### About MedTech Innovator 2017

MedTech Innovator is the industry's nonprofit global competition and accelerator. Its mission is to improve the lives of patients by accelerating the growth of companies that are transforming the healthcare system. MedTech Innovator is the largest platform of its kind, providing participants with broad exposure and mentorship from the leading players in the medtech industry. In 2017, MedTech Innovator will give out over \$500K in cash prizes.

##### MedTech Innovator Criteria

MedTech Innovator seeks early to mid-stage startups, including medical device, diagnostic, and digital health technologies addressing the following industry-selected themes:

Chronic Disease Management

Cognitive Devices and Platforms

Consumer Healthcare

Healthcare Efficiency and Cost Reduction

Infectious Disease Management

Next-Gen Surgical

Patient Safety and Satisfaction

Population Health; Precision and Personalized Medicine and Technology Enabled Services

##### Program Participant Benefits

Companies selected to participate in the MedTech Innovator Accelerator receive: Mentorship from leading investors, manufacturers, providers, payers, IP, regulatory and reimbursement professionals, and others.

Exclusive participation in the three-day MedTech Innovator Accelerator Kick-Off in San Francisco.

A chance to compete onstage for \$500,000 in cash prizes and more.

\*\*\*\*\*

#### **Triple Ring Technologies, Thursday Evening, April 6, 2017**

Topic: "The Future of Immuno-Neurology"

Speaker: Rich Casey, CEO, Neuraltus Pharmaceuticals

Date and Time: Thursday, April 6, 2017, 6:00 – 9:00 pm

Location: Triple Ring Technologies 39655 Eureka Drive, Newark

Cost: The seminar is free, but registration is required for planning purposes

Register at <https://goo.gl/bSyV8r>

#### Event Description

While many academic and industrial laboratories are pursuing research on the fundamental

genetics of neurodegenerative diseases, there is a growing interest in how the immune system interacts with the nervous system and how certain immune cells can be modulated to slow down or even reverse the ravages of diseases such as ALS, Alzheimer's, Parkinson's, and Frontotemporal Dementia. This talk will focus on the role of the immune system in neurological disorders and the efforts Neuraltus Pharmaceuticals is undertaking to develop NP001, a small molecule modulator of immune function, for the treatment of ALS (Lou Gehrig's Disease).

#### Speaker Bio

Rich Casey has spent his entire 40-year career in the pharmaceutical and biotechnology industries. He is currently CEO of Neuraltus Pharmaceuticals, which is developing a drug for ALS (Lou Gehrig's Disease). For eleven years, he was Chairman and CEO of Scios, Inc., a biotech company in the areas of cardiovascular disease and inflammation. Under his leadership, Scios successfully developed Natrecor (nesiritide), a leading treatment for acute congestive heart failure. Scios was sold in 2003 to Johnson & Johnson.

Earlier in his career, Rich worked in a variety of marketing, sales, and general management positions at Eli Lilly, Syntex, and Alza. He received both his BS degree (Chemistry, 1968) and his MBA (1973) from Stanford University. From 1968 to 1970, Rich served in the Peace Corps in Ethiopia as a producer and writer of science and mathematics programs for educational television.

We're in an industrial park with plenty of parking. Should you have questions or comments, feel free to email us at [mtf@tripleringtech.com](mailto:mtf@tripleringtech.com)

\*\*\*\*\*

### **Bio2Device Group, Tuesday Evening, April 11, 2017**

Topic: "Integrated, Intelligent SmartDermal™ Therapeutics"

Event Date:

Speaker: Patrick Ruane, Ph.D., Senior VP Research and Development, Chrono Therapeutics

Date and Time: Tuesday, April 11, 2017, 6:00pm

Location: Wilson Sonsini Goodrich & Rosati - 650 Page Mill Road, Palo Alto

Cost:

\$6 - Students/In-transition - Members only

\$11 - Early-bird Registration - Members only

\$20 - Late Registration and Non-Members

\$25 - Walk-ins

Register at [www.Bio2DeviceGroup.org](http://www.Bio2DeviceGroup.org)

Payment Options April 11th Event

We use PAYPAL to process your online payment. Print and bring a copy of your online receipt with you. If space permits, walk-ins are welcomed; please be prepared to pay \$25 cash or check. There is no refund, exchange, or transfer. Thank you for your cooperation. To register now, select the appropriate registration level and your meal preference from the pull-down menus below and enter the name and email of the attendee. Then click on the "Pay Now" button to reach the PayPal payment page. Each attendee must be registered separately. Please register a non-member by logging out first.

#### Topic Description

Patrick will describe the technology, the challenges associated with developing this technology (Drug, Medical Device and Technology rolled into a single product) and outline

how the technology can be used as a platform for transdermal drug delivery in the treatment of Smoking Cessation, Parkinson's Disease and Opioid Tapering. He will also discuss Regulatory, Clinical and Business strategy if people are interested, and will bring their product along for you to view.

#### Speaker Bio

Dr. Ruane has nearly 2 decades of experience in drug delivery for combination medical devices. He most recently served as Vice President of R&D at CV Ingenuity (acquired by Covidien) and has held various positions in R&D at Xtent, Cook Group and Navigant Biotechnologies.

Dr. Ruane received his primary degrees in Chemistry from The Galway-Mayo Institute of Technology and Trinity College Dublin, his Ph.D. from University College Dublin and Post-Docs at University of Toronto and The Johns Hopkins University. He is published extensively in both the academic and patent literature.

Chrono Therapeutics (CHRONO) is a pharmaceutical company with a vision of transforming disease and addiction management to become the market leader in programmable passive transdermal drug delivery (TDD) that offers real-time behavioral support. Chrono's executive leadership combines years of professional experience and personal passions for developing life-saving medical products.

\*\*\*\*\*

#### **CLSA, Tuesday MidDay, April 11, 2017**

Event: Lunch & Learn Series: Lunch & Learn - Common Stock Valuations: Myths and Reality

Speakers: Angela Rusakova, Lead Client Service and Audit Partner; *Camron Uhr, Managing Director, Deloitte Transactions and Business Analytics LLP*

Date and Time: Tuesday, April 11, 2017, 11:00am - 2:00pm PT

Registration & Lunch: 11:00 am - 11:30 am

Program: 11:30 am - 12:30 pm

Networking: 12:30 - 1:00pm

Location: CLSA Events Center, 250 E. Grand Ave, Ste 26, South San Francisco, CA 94080

Fee: Member: Complimentary (CLSA Membership will be verified upon registration. To check membership status visit our directory).

Non-Member: \$75

Register at [https://www.eventbrite.com/e/lunch-learn-common-stock-valuations-myths-and-reality-tickets-](https://www.eventbrite.com/e/lunch-learn-common-stock-valuations-myths-and-reality-tickets-32366748817?utm_source=Master+List&utm_campaign=e5491e8771-EMAIL_CAMPAIGN_2017_03_15&utm_medium=email&utm_term=0_a9171f83c7-e5491e8771-196415673)

[32366748817?utm\\_source=Master+List&utm\\_campaign=e5491e8771-](https://www.eventbrite.com/e/lunch-learn-common-stock-valuations-myths-and-reality-tickets-32366748817?utm_source=Master+List&utm_campaign=e5491e8771-EMAIL_CAMPAIGN_2017_03_15&utm_medium=email&utm_term=0_a9171f83c7-e5491e8771-196415673)

[EMAIL\\_CAMPAIGN\\_2017\\_03\\_15&utm\\_medium=email&utm\\_term=0\\_a9171f83c7-e5491e8771-196415673](https://www.eventbrite.com/e/lunch-learn-common-stock-valuations-myths-and-reality-tickets-32366748817?utm_source=Master+List&utm_campaign=e5491e8771-EMAIL_CAMPAIGN_2017_03_15&utm_medium=email&utm_term=0_a9171f83c7-e5491e8771-196415673)

#### Topic Description

Common Stock Valuations: Myths and Reality

Is your company issuing stock and share-based awards for services to employees, directors and consultants? Then you probably know what a 409a valuation is. But, are you familiar with which valuation methodologies are most appropriate at a particular stage of the company's development? Can you have one valuation methodology for IRS and one for financial reporting purposes? Join us for a lunch to discuss some myths and realities around 409a valuations.

- 409a valuation - when should you prepare one
- 409a vs. US GAAP valuation
- Valuation methodologies
- Fair values of common and preferred stock
- Pre-IPO valuations SPONSORED BY:  
<http://califesciences.us2.list-manage1.com/track/click?u=ac3d0585c9793eba2bcaf4046&id=426f171dad&e=bd3a594c11>

Deloitte professionals will share their experiences working with start-up life sciences companies and answer your questions about common stock and company valuations. The skills learned during this program will be valuable to you in communications with your boards, IRS, auditors, and bankers throughout your company's life cycle.

**Speakers Bios**

Angela has over 20 years of experience serving both public and private companies with a focus on the life sciences industry. She works with companies in all stages of growth, from start-ups to SEC registrants. Her technical background includes complex accounting issues such as revenue recognition, equity, derivatives, stock-based compensation, and acquisitions. Angela has been involved in financing and M&A transactions, including initial public offerings, debt and common stock offerings, leveraged buyouts and acquisitions. She has extensive international experience and is a certified public accountant in the United States and the United Kingdom. Angela also served as a CFO before returning to public accounting in 2003.

Camron M. Uhr is a Managing Director with Deloitte Advisory specializing in business valuation services. Mr. Uhr has thirteen years of experience performing business and asset valuations for advisory and financial reporting purposes. Currently, Mr. Uhr emphasizes in valuations for financial reporting purposes, including: ASC 350 and 805 compliance, 409A and ASC 718 option valuation, and valuations of privately-held common and preferred stock. Additionally, Mr. Uhr also provides audit support services for Deloitte & Touche LLP performing statement of audit support ("SAS") 101 reviews of fair value estimates to be used in the financial statements of Deloitte & Touche LLP audit clients. Prior to joining Deloitte, Mr. Uhr was employed as a Senior Analyst for a boutique investment banking and valuation services firm.

Mr. Uhr holds a Bachelor of Science degree in Business Administration, with an emphasis in Finance, from the University of California, Riverside and a Masters of Business Administration from California State University, Fullerton.

\*\*\*\*\*

**WIB, Wednesday Evening, April 12, 2017**

Subject: WIB-National Webinar "Risky Business: Mitigating Risk in the Life Sciences"  
 Speaker: Gretchen Stup, Sr. Consultant at Latham Biopham Group  
 Date and Time: April 12, 2017, 1:00 p.m. – 2:00 p.m. EST\*  
 \*- Please note this webinar's time is listed in Eastern Standard Time.  
 Pricing Information  
 Members: Free  
 Non-Members: \$30

\* - Registrants will be sent a specific GoToMeeting link to access the webinar. Please be sure to click on the link before the webinar to ensure the program is properly installed on your computer.

Register at <http://womeninbio.org/eventdetails.aspx?EventId=30877>

Registration Deadline

April 11, 2017

Registrants will receive a webinar link via confirmation email

#### Webinar Description

Inviting. Supporting. Succeeding.

All projects present risk, and successful project managers recognize that it is vital not to avoid risks, but to understand them. Risk management is the process of identifying, assessing, mitigating, and controlling the known risks in order to increase the probability of meeting your project objectives. By planning for unexpected events, you can be ready to respond if they arise. This webinar will be led by Gretchen Stup, Senior Consultant, Latham BioPharm Group, and will bring to light the importance of Risk Management as well as introduce methods and tools that can be implemented to ensure a successful risk management process. Gretchen will utilize a slide presentation and will review specific examples to help illustrate the key concepts of Risk Management. The presentation will help you understand how to identify what can go wrong, how to assess a risk events probability and impact, and what to do to lessen the probability or impact of a risk event occurring. Real-world examples and considerations from the speaker's professional experience will be highlighted during the webinar. In addition, there will be time allotted for questions and answers at the conclusion of the webinar.

This course will result in up to one hour of PMI-approvable Professional Development Units (PDUs) for the project management field.

Learn more and register for this event.

#### Speaker Bio

About Gretchen Stup: Gretchen has over 16 years of experience in the management of government contracts, and over 18 total years of experience working in a scientific environment. She is currently a Sr. Consultant at Latham Biopharm Group where she provides program management and systems integration support to government and client related projects. Prior to this, she served as a Sr. Project Manager for DynPort Vaccine Company (DVC) where she managed a >\$350 M DoD advanced vaccine development contract and a smaller NIAID R&D contract. She has experience in total project lifecycle management, with a focus on managing and integrating the activities of numerous functional areas, including finance, manufacturing, nonclinical, quality, clinical, and regulatory personnel, and managing project related subcontractors. Prior to working in Program Management, Gretchen co-developed and implemented DVC's comprehensive Risk Management program. She has a Bachelor of Science degree from Shepherd University and is a Project Management Professional (PMP) as certified by the Project Management Institute.

Walk-Ins Accepted?

Walk-ins are not accepted – be sure to register early!

\*\*\*\*\*

#### **Bio2Device Group, Tuesday Morning, April 18, 2017**

Topic: "The Digital Health Revolution: Challenges and Opportunities"

Date and Time: Tuesday, April 18, 2017, 8:30 am

Location: Sunnyvale City Council Chambers- 456 West Olive Ave., Sunnyvale

There is no registration or fees for morning meetings.

Topic Description

With \$4B in venture funding last year and over 200,000 medical apps currently available for download, digital health has captured the attention of investors, entrepreneurs, and tech giants across the US. The current digital health landscape includes a broad range of technology solutions that span different applications, from consumer wellness to telemedicine to data analytics. These solutions address healthcare across the entire spectrum, from self-management in the home to ambulatory and hospital care.

Despite growing enthusiasm and consumer adoption of digital health solutions, significant barriers make it difficult for early stage digital health companies to scale effectively or reach profitability. These barriers include physician and patient adoption, a lack of data to substantiate improved health outcomes and cost savings, limited integration into clinical workflows and EHRs, reimbursement challenges, and regulatory hurdles. A complex, fragmented healthcare system that continues to struggle with interoperability further magnifies these barriers.

Where will digital health solutions have the greatest impact? How can companies address these barriers to accelerate adoption? In what ways can stakeholders better coordinate their efforts within the digital health ecosystem? Using stories and examples, this session will dig deeper into the largest opportunities and hardest challenges that digital health will face in the future.

Speaker Bio

Anne Merritt, MD, is an academic physician and healthcare consultant with over ten years of experience in healthcare technology, patient safety, and quality improvement. She is currently a Clinical Instructor in Emergency Medicine at Stanford University. As a physician leader, she has developed strategies to engage physicians in professional development and managed cross-functional teams to improve health outcomes and the patient experience. She has also been an invited speaker at national medical conferences. In addition to her clinical work, she works with Life Science Angels, a premier angel investment group focused on biotech, digital health, medical devices, and diagnostics. She also works as a consultant and advisor to digital health and medical device companies. She earned her medical degree from Yale University and her business degree from Stanford Graduate School of Business.

\*\*\*\*\*

**JLABS, Tuesday Morning, April 18, 2017**

Topic: "Meet with the Gates Foundation"

Speaker: Charlotte Hubbert, PhD | Partner, Gates Foundation Venture Capital

Location: JLABS @ SSF, 329 Oyster Point Blvd - 3rd Floor, South San Francisco, California

Date and Time: Tuesday, April 18, 2017, 10:30 am

Agenda:

10:30am | Registration & Networking

11:00am | Company Presentation and Q&A

11:45am | Lunch & Networking

12:45-5:00pm | One-on-one Meetings\*

\*Companies must have apply ahead of time and be approved for a one-on-one meeting. Application period ends March, 13, 2017. Apply Here.

Fees:

Presentation

\$25 | General Public

\$35 | Onsite

Includes presentation, Q&A, and lunch. All attendees must pay this fee, regardless of one-on-one meeting status. Pre-registration to attend the presentation, Q&A, and lunch will remain open until 12:30pm on April 18th (or sold out).

One-on-One Meeting

FREE | Application

FREE | Accepted Companies

Companies must have applied for a one-on-one meeting ahead of time. The one-on-one application period will close on March 13, 2017. Your application will be reviewed and you will be notified of acceptance by March 30, 2017. Acceptance of one-on-one meeting is not guaranteed as all applications must be approved

Registration at <https://www.eventbrite.com/e/meet-with-the-gates-foundation-tickets-29533732188?aff=weekly>

Program Overview:

The path out of poverty is paved with access to quality healthcare. Do you have solutions that will make a difference? The Bill & Melinda Gates Foundation is advancing science and technology to save lives in developing countries. The Foundation works with partners to deliver proven tools—including vaccines, drugs, and diagnostics—and discover ground breaking new solutions that are affordable and reliable. Focus areas for investments center on infectious diseases including HIV, polio, TB, dengue and malaria, as well as diagnostics and health IT ideas that bring health interventions to people who need them most.

Charlotte Hubbert, Partner with Gates Foundation Venture Capital, will be in attendance to provide an overview presentation on the Foundation's key areas of interest and venture investment philosophy. Gates Foundation Venture Capital operates under the Program Related Investments group at the Bill & Melinda Gates foundation, which manages a \$1.5B allocation for private sector investment. Charlotte will be on hand to meet with a handful of applicants one-on-one after the presentation. To be considered for a one-on-one meeting complete the information required at the link below.

Speaker Bio

Charlotte Hubbert is a Partner with Gates Foundation Venture Capital, investing innovative technologies that support The Bill & Melinda Gates Foundation initiatives in Global Health and Agriculture. Prior to joining the Gates Foundation, Charlotte was a Vice-President at H.I.G. BioVentures focusing on investment opportunities in the life sciences, including therapeutics, diagnostics and medical devices at all stages of development. She was BOD observer at Cardeas Pharma and Alder Biopharmaceuticals. Charlotte started her career in early stage biotech investing at Accelerator Corporation, an investment vehicle focused on identifying, evaluating, financing and managing emerging therapeutic technologies. During her tenure, Charlotte was involved in the strategic development and management of five companies, including Oncofactor, Groove Biopharma, Acylin Therapeutics, Xori and Pharmselex. Charlotte currently serves as an observer on the board of directors of Synlogic, Sera Prognostics and Lodo Therapeutics.

Charlotte earned a B.S. in Microbiology from the University of Washington and a Ph.D. in Pharmacology and Cancer Biology from Duke University. She did her post-doctoral work in stemcells and regenerative medicine at the Institute for Stem Cells

and Regenerative Medicine at the University of Washington. Charlotte is a member of the Kauffman Society of Fellows (Class 14).  
Connect with Charlotte: Connect on LinkedIn

About the Meet with... Series:

The purpose of the Meet with Series events sponsored by JLABS is to help start-up entrepreneurs, as well as the academic community, connect with potential partners, such as big pharma or other investment corporations, through one-on-one meetings. It is also a chance for the featured corporation to outline their specific business development goals and clarify what types of products or research they are interested in and how best to approach them to get the partnering process started. Past participants include the Wellcome Trust, Bill & Melinda Gates Foundation, MedImmune Ventures, Mercury Fund, DARPA's Biological Technologies Office, Correlation Ventures, Breakout Labs, New Enterprise Associates, Canaan Partners, Thomas McNerney & Partners, NCI, NCATS, NINDS, Allegory Venture Partners, Clarus Ventures, Johnson & Johnson Innovation, California Institute for Regenerative Medicine, Astellas Venture Management, and OrbiMed.

\*\*\*\*\*

**EMBS, Wednesday Evening, April 19, 2017**

Topic: "Study of Fluorescence Spectroscopy Guided Optical Biopsy Needle for Prostate Cancer Diagnosis"

Speaker: Amir Tehrani, Chief Executive Officer, Precision Biopsy, LLC

Date and Time: Wednesday, April 19, 2017, 7:30 pm

Location: Room M-114, Stanford University Medical School (see campus map at link below)

Optional dinner location: Stanford Hospital cafeteria, 6:15 PM (no host, no reservations, self-serve)

[http://maps.stanford.edu/sites/all/lbre-shared/files/maps/files/shared/file/maps\\_records/Parking\\_And\\_Circulation\\_Map.pdf](http://maps.stanford.edu/sites/all/lbre-shared/files/maps/files/shared/file/maps_records/Parking_And_Circulation_Map.pdf)

Parking is usually free after 5 PM at Roth Way Garage, which is at the corner of Roth Way and Campus Drive West (E-7) on the map. The Stanford Hospital Cafeteria is near the Emergency entrance, at D-6 on the map. The Medical School is across Campus Drive West from Roth Way Garage, and Room M114 is accessible from outside the building at E-6 on the map.

Topic Description

Current prostate biopsy cores have a very low diagnostic yield. These biopsies often fail to diagnose prostate cancer since 90% of cores are histopathologically classified as benign. The concentrations of endogenous fluorophores in prostate tissue vary with disease states. Thus, fluorescence spectroscopy could be utilized to quantify these variations for identification of malignant lesions. We investigated clinical feasibility of a 14 gauge (1.98 mm) optical biopsy needle guided by fluorescence spectroscopy for real-time in vivo prostate cancer diagnosis. Built-in optical sensor has 8x100µm fibers for tissue excitation and a single 200µm fiber to collect spectral data. Custom-made fluorometer has 2 light-emitting diodes at 290 and 340 nm and a spectrometer. User interface for fluorometer operation and data collection was developed using LabView software. Each spectral data acquisition required ~2 seconds. The in vivo biopsies were performed during radical retropubic prostatectomy surgery on the exposed prostate with blood flow to the gland intact. A tissue biopsy core was obtained from each biopsy site after acquisition of spectral data. Above procedure was repeated ex vivo after surgical excision of the prostate. Biopsy cores were histopathologically classified as either benign or malignant and correlated with

corresponding spectral data. Partial Least Square analysis was performed to determine diagnostically significant principal components as potential classifiers. A linear support vector machine and leave-one-out cross validation method was employed for tissue classification. Thirteen patients were consented to the study. Histopathological analysis found cancer in 29/208 in vivo and 51/224 ex vivo viable biopsy cores. Study results show 72% sensitivity, 66% specificity, and 93% negative predictive value for in vivo and 75%, 80%, and 93%, respectively, for ex vivo malignant versus benign prostatic tissue classification. Optical biopsy needle has a very high negative predictive value to indicate benign tissue while sufficient sensitivity for targeting areas suspicious for cancer within the prostate gland. Hence, the optical biopsy needle can increase the diagnostic yield of prostate biopsies with consequent improvement in patient care.

#### Speaker Bio

Precision Biopsy is led by CEO Amir Tehrani, who has over 20 years' of experience in management and operations, strategy, business development, marketing, design and development for Fortune 500 and start-up medical device companies. Prior to Precision Biopsy, Amir was the President and CEO of Amaranth Medical, Inc., a bioabsorbable stent company. He has been instrumental in the formation and financing of several medical device companies, including Inspiration Medical, Inc., Corventis, Inc. (acquired by Medtronic, Inc.), Spinal Modulation, Inc., (acquired by St. Jude Medical), Sonitus Medical, Inc., and RODO Medical, Inc. Amir also led successful investments and acquisition in the medical technology sector at Guidant Compass Group. He also held several leading marketing and engineering positions at Guidant Vascular Intervention, St. Jude Medical CRM Division, Ventritex, Inc., (acquired by St. Jude Medical), and MiniMed, Inc. (acquired by Medtronic, Inc.). Amir holds a BS in Electrical Engineering from the University of Idaho and an MS in Biomedical Engineering from California State University in Sacramento, CA.

\*\*\*\*\*

#### **PBSS Symposium, Monday, April 24, 2017**

*Topic: "Mechanistic Drug Metabolism for Drug Candidate Optimization – A Mini-symposium for Medicinal Chemists and DMPK Scientists"*

Organizers: Cyrus Khojasteh and Donglu Zhang (Genentech)

Date and Time: April 24, 2017, 8:45-17:00

Location: Crowne Plaza, Foster City, CA

Registration fee (USD): Minisymposium fee: \$195;

Registration: <http://www.PBSS.org>

Registration deadline: 4/20/2017 (it will close sooner if the seating cap is reached)

#### Topic Description

Drug metabolism and pharmacokinetics (DMPK) plays an integral role in drug discovery. At drug discovery stage, mechanistic drug metabolism studies contribute to generating drug candidates with optimal ADME properties and in some cases it allows for overcome potential drug development obstacles such as toxicity and DDI that are often encountered in drug discovery and development. In this one-day symposium, multiple examples will be presented to illustrate the utilities of mechanistic drug metabolism in moving discovery and development programs forward. Medicinal chemists and drug metabolism scientists should greatly be benefited from participating in this symposium.

#### Tentative topics and speakers:

Morning: 8:45-12:00

Overview on drug metabolism and its role in lead optimization - Cyrus Khojasteh, Genentech

Hepatocyte spheroid models and applications in drug metabolism - Jinping Gan, BMS

Sponsor presentation

Drug metabolism tools to assess bioactivation potential of drug candidates - minimizing metabolism-related DILI or genotoxicity - Zhoupeng Zhang, Merck  
Prediction of circulating drug metabolites - Ming Hu, University of Houston

Afternoon: 1:15-5:00

Inhibition of endogenous metabolic pathways leading to toxicities - Donglu Zhang, Genentech

Sponsor presentation

Discovery of Bioavailable Pim Inhibitors by Mitigating Intestinal Metabolism – Gina Wang, Genentech

Metabolism-based structure-activity relationship analysis for identification of a PI3K inhibitor clinical candidate devoid of target hepatotoxicity - Raju Subramanian, Gilead

Minimizing reversible and time-dependent CYP inhibition of NAMPT (nicotinamide phosphoribosyltransferase) inhibitors - Mark Zak, Genentech

Carboxylic acid bioactivation via glucuronides/acyl CoA's and application in drug discovery – Mark Grillo, Amgen

\*\*\*\*\*

**JLABS Bay Area, Tuesday Mid Day, May 2, 2017**

Topic: "Money Matters - Insider Tips on Raising Money"

Speaker: Julie Papanek, Partner, Canaan Partners

Date and Time: Tuesday, May 2, 2017, 10:30 am – 1:00 pm

Agenda:

10:30 AM | Registration and Networking

11:00 AM | Presentation

11:30 AM | Q&A

12:00 PM | Food and Networking

1:00 PM | Program Close

Fees:

\$25 | General Public

\$15 | Student

\$45 | At the door

Location: JLABS @ SSF, 329 Oyster Point Blvd - 3rd Floor, South San Francisco, California

Order at <https://www.eventbrite.com/e/money-matters-insider-tips-on-raising-money-tickets-32167293240?aff=weekly>

Speakers Bio

Julie Papanek is a Partner at Canaan Partners where she concentrates on biopharmaceutical, digital health and consumer medical device investments. Julie currently sits on the board of Protagonist Therapeutics (PTGX) and has also worked closely with and observed on the boards of CytomX, Labrys Biologics, Dermira, ALDEA Pharmaceuticals, Chrono Therapeutics, and Glooko. Prior to Canaan, Julie worked at Genentech in a variety of positions spanning marketing, development, and business development.

Julie earned her MBA from Stanford's Graduate School of Business, MPhil from Cambridge in BioScience Enterprise and B.S. from Yale in Molecular Biophysics and Biochemistry.

\*\*\*\*\*

**QB3, Late Thursday Afternoon, May 11, 2017**

Topic: "Leadership in Biopharma: a Conversation with John Milligan, CEO of Gilead Sciences"

Speakers: John Milligan, CEO, Gilead Sciences; Harold E. "Barry" Selick, Ph.D. CEO, Threshold; Brook Byers, Founding Partner of Kleiner Perkins Caufield & Byers

Date and Time: Thursday Afternoon, May 11, 2017, 4:00 – 6:30 pm

Agenda

4:00 pm Introduction: Brook Byers, Partner, Kleiner Perkins Caufield & Byers

4:00-5:00 pm Remarks from John Milligan, Gilead Sciences, followed by audience Q&A and a conversation moderated by Barry Selick, Threshold Pharmaceuticals

5:00-6:30 pm Reception

Location: Byers Auditorium, Genentech Hall, Byers Auditorium, Genentech Hall, UCSF Mission Bay, 600 16th Street. San Francisco, CA 94158

4:00 to 5:00 pm, Thursday, May 11. Reception to follow

Registration is free. Register at [https://www.eventbrite.com/e/leadership-in-biopharma-a-conversation-with-john-milligan-ceo-gilead-sciences-tickets-32902967662?mc\\_eid=cb4c38a44a&mc\\_cid=c37eecb250#tickets](https://www.eventbrite.com/e/leadership-in-biopharma-a-conversation-with-john-milligan-ceo-gilead-sciences-tickets-32902967662?mc_eid=cb4c38a44a&mc_cid=c37eecb250#tickets)

Background

Gilead Sciences is a Bay Area titan, a life science leader known for its pipeline of antivirals and Hepatitis C therapeutics. Its CEO is John F. Milligan, PhD, a former UCSF postdoc, who joined the company in 1990 as its 32nd employee. Join us on May 11 when Barry Selick, CEO of Threshold Pharmaceuticals and himself a former UCSF postdoc, will engage Milligan in a conversation touching on topics such as Milligan's career path from postdoc to CEO of a major biotech, his experience leading it, and how Gilead feeds its pipeline of innovation and develops new products.

Brook Byers, a Founding Partner of Kleiner Perkins Caufield & Byers and a member of the UCSF Board of Overseers, will provide introductory remarks.

Speaker Bio

Dr. John F. Milligan joined Gilead Sciences in 1990 and was appointed Chief Executive Officer in March 2016. He began his career at Gilead as a research scientist, and subsequently held leadership positions in project management and corporate development before being named Chief Financial Officer in 2002. He was appointed Chief Operating Officer in 2007 and President in 2008.

During his tenure at Gilead, Dr. Milligan has led teams that have developed, manufactured and commercialized more than 20 new therapies for significant unmet needs. He has managed multiple transformative acquisitions, licensing agreements and financings, helping the company grow into a worldwide organization reaching more than 10 million patients. He is a member of the board of Pacific Biosciences of California, Inc. and a Trustee of Ohio Wesleyan University.

Harold E. "Barry" Selick, Ph.D. joined Threshold as Chief Executive Officer in June 2002. Between June 2002 and July 2007, Dr. Selick was also a Venture Partner of Sofinnova Ventures, Inc., a venture capital firm. From January 1999 to April 2002, he was Chief Executive Officer of Camitro Corporation, a biotechnology company that was acquired by ArQule. From 1992 to 1999, he was at Affymax Research Institute, the drug discovery technology development center for Glaxo Wellcome plc, most recently as Vice President of Research. Prior to working at Affymax he held scientific positions at Protein Design Labs, Inc. and Anergen, Inc. As a staff scientist at Protein Design Labs, he co-invented the technology underlying the creation of fully

humanized antibody therapeutics and applied that to PDL's first product, Zenapax, which was developed and commercialized by Roche for the prevention of kidney transplant rejection. Dr. Selick received his B.S. and Ph.D. from the University of Pennsylvania and was a Damon Runyon-Walter Winchell Cancer Fund Fellow and an American Cancer Society Senior Fellow at the University of California, San Francisco.

Brook Byers is a Founding Partner of Kleiner Perkins Caufield & Byers. A venture capital investor since 1972, Brook has been closely involved with more than 60 new technology-based ventures, many of which have become public companies. He formed the first life sciences practice group in the venture capital profession in 1984 and led KPCB to become a premier venture capital firm in the medical, healthcare and biotechnology sectors. KPCB has invested in and helped build more than 170 life sciences companies that have developed hundreds of products to treat underserved medical needs for many millions of patients. Brook was the founding president and then chairman of four biotechnology companies that were incubated in KPCB's offices and went on to become public companies with an aggregate market value of more than US\$8 billion. He serves on the board of directors of Cell Design Labs, Enjoy, Newsela and Zephyr Health. Brook is also a Lifetime Director on the UCSF Board of Overseers.

\*\*\*\*\*

**BioPharma PM Conference, Monday-Tuesday, May 22-24, 2017**

Event: Stepping Up and Stepping Out

Dates: Monday, Tuesday and Wednesday, May 22-24, 2017

Program:

May 22

5:00-7:00PM: Registration and Opening Networking Reception

May 23

7:30-9:00AM: Registration and Breakfast Networking

9:00AM-5:00PM: Conference Presentations, Panels, Workshops

5:00-7:00PM: Evening Networking Reception

May 24

7:30-9:00AM: Breakfast Networking

9:00AM-2:30PM: Conference Presentation, Panels, Workshops

2:30PM: Conference Conclusion

Location: San Mateo Marriott San Francisco Airport, 1770 South Amphlett Boulevard, San Mateo, CA 94402

Registration: Early Bird Registration (through March 31): \$695 (plus payment processing fees); Regular Conference Registration (after March 17): \$895 (plus payment processing fees); All registrants will receive a complimentary one-year BioPharmaPM Network membership (a \$50 value).

Register at <https://www.eventbrite.com/e/2017-biopharmapm-conference-tickets-31937261208>

**Event Description**

Please join us for the 2017 BioPharmaPM Network Conference! We are planning an exciting program for you. Below are a few of our featured speakers, panelists, and trainers who will speak on diverse topics such as managing your career in alignment with your values, leadership development in project management, and how you can solve problems inhibiting project success easily and effectively.

Speakers: William Schiemann, Founder and CEO of Metrus Group and Author;

Jean Lee, Ph.D., Vice President, Portfolio and Project Management at Pfizer Global Product Development; Michael Young, Chief Learning Officer and SVP of Education at the The Medicines Company; Mark Velligan, Senior Director of Portfolio Management and Operations at Genentech; Trevi Wormley, Managing Director and Chief Solution Engineer at TJ Strategy Group, LLC

We hope you will join us at the San Mateo Marriot in San Francisco May 22-24 and be a part of the only non-profit organization solely committed to project management best practices, development, and networking for biopharma project and program managers.

#### FAQs

How can I contact the organizer with any questions?

For questions, please contact Kelly Magnuson at kmagnuson@biopharmapm.org

How do I make room reservations?

We are holding a few rooms at a discounted rate with the San Mateo Marriott. If you require a room, please email Kelly Magnuson at kmagnuson@biopharmapm.org for details.

\*\*\*\*\*

#### **JLABS, Tuesday Morning, May 23, 2017**

Topic: "Rough seas or smooth sailing? Navigating Collaboration Agreements"

Speakers:

Angela Rusakova | Lead Client Service and Audit Partner, Deloitte & Touche LLP

Yelda Kaya | Sr. Director Transactions, Johnson & Johnson Innovation

William J. Newell | CEO, Sutro Biopharma

Moderator: Lesley Stolz | Head of JLABS, CA, Johnson & Johnson Innovation, JLABS

Date and Time: Tuesday, May 23, 2017 from 9:00 AM to 11:30 AM (PDT)

Agenda:

9:00 AM | Registration, Breakfast, and Networking

9:30 AM | Components of a collaboration agreement

10:00 AM | Panel Discussion: Implications of Components

11:00 AM | Q&A

11:30 AM | Program Close

Location: JLABS @ SSF, 329 Oyster Point Blvd - 3rd Floor, South San Francisco, California

Fees:

\$25 | General Public

\$15 | Student

Order at <https://www.eventbrite.com/e/rough-seas-or-smooth-sailing-navigating-collaboration-agreements-tickets-32071988180?aff=weekly>

#### Event Details

How do you develop a smart collaboration agreement? An effectively written collaboration agreement builds and strengthens a productive scientific relationship by allowing parties to enter into a mutually beneficial relationship.

How do you make sure the agreement will fit your company objectives? An effective agreement should be clear, to both the research workers and managers of both parties, laying the groundwork for moving the results of research toward commercialization. It addresses the nature of the collaboration, the responsibilities

and obligations of each party, the desired outcomes and next steps beyond the currently contemplated research.

At this event, we will walk through building components of a collaboration agreement, point out and discuss key terms and provisions that help make a quality agreement. The talk will provide real world examples and focus on the following topics:

Intro to Collaboration Agreements / General provisions

Statement of objectives/work

Budget

IP

Restrictions and opportunities created by agreements

Real world examples from panel members

The panel members will share real life experiences through the R&D collaboration process and beyond. The workshop will examine key types of provisions and their effects on future development and funding opportunities. This "how to" workshop is geared towards life sciences startup

Guests will be provided supporting materials including:

Key provisions guide

Sample Collaboration agreements

This event is being hosted in conjunction with Deloitte. Deloitte is deeply committed to the life sciences industry. As an advisor to many leading health care and life sciences organizations, Deloitte has been instrumental in developing and implementing many strategies that helped shape the evolution and long-term success of this industry. At Deloitte, we serve from early-stage companies to the world's largest players. We know where you go and we can help you to realize your dreams. As with all our events, the "How to...Workshop" is informal and interactive so bring your questions with you!

#### Speakers' Biographies:

Angela Rusakova | Lead Client Service and Audit Partner, Deloitte & Touche LLP  
Angela has 20 years of experience serving both public and private companies with a focus on the life sciences industry. She works with companies in all stages of growth, from start-ups to SEC registrants. Her technical background includes complex accounting issues such as revenue recognition, equity, derivatives, stock-based compensation, and acquisitions. Angela has been involved in financing and M&A transactions, including initial public offerings, offerings in leveraged buyouts, and several secondary shares offerings. She has extensive international experience and is a certified public accountant in the United States and the United Kingdom. Angela also served as a CFO before returning to public accounting in 2003.

Yelda Kaya | Sr. Director Transactions, Johnson & Johnson Innovation  
Yelda is the Senior Director of Transactions in Johnson & Johnson Innovation Center, California.

Leveraging a diverse career practicing emergency medicine, corporate law and business development, Yelda brings extensive experience to transactions delivering a unique breadth of deals across sectors with an established track record of successfully leading, structuring, negotiating and executing complex deals over the last 10 years.

Yelda joined the Johnson & Johnson family from GSK's worldwide business development group. She holds a MBBS, LLB and MBA from the University of Melbourne.

William J. Newell | CEO, Sutro Biopharma

Mr. Newell has over 24 years of senior management experience in the biotechnology industry. He joined Sutro Biopharma as CEO in January 2009. Previously, he served as the President of Aerovance, Inc., a venture-backed company developing clinical assets for respiratory diseases. Mr. Newell also was Chief Business Officer and Senior Vice President at publicly-traded QLT, Inc. and served in several senior management positions at public-traded Axys Pharmaceuticals, Inc. For the 16 years prior to joining Axys, Mr. Newell practiced corporate law in the San Francisco Bay Area. He is presently a member of the Board at Symic Bio. Mr. Newell is also a Board member on BIO's Emerging Companies Section and a member of the Board and of the Executive Committee of the California Life Sciences Association.

Lesley Stolz | Head of JLABS, CA, Johnson & Johnson Innovation, JLABS

Dr. Stolz has 20 years of business and corporate development experience working for companies that have been both technology platform and therapeutics focused. After two years negotiating partnering deals for Johnson & Johnson Innovation at the California Innovation Center, Lesley joined the JLABS team as Head of JLABS, CA, to participate in the mission of helping to catalyze new companies in the healthcare ecosystem. Prior to joining Johnson & Johnson Innovation, she held executive positions with BioTime, Inc., Sutro Biopharma, Inc., and Sunesis Pharmaceuticals where she was responsible for corporate strategy, fundraising and all aspects of partnering. Earlier in her career, she served as Senior Director, Business Development for Aerovance, Inc. and for GPC Biotech AG in Munich, Germany from 2002 to 2006. She also served in senior management positions at Cell Genesys, Discovery Partners International and Axys Pharmaceuticals. During her career she has work on over 45 collaboration agreements helping shape effective opportunities for early stage companies. Dr. Stolz received her Ph.D. in chemistry, and conducted postdoctoral research at Harvard Medical School's Department of Biochemistry and Molecular Pharmacology.

\*\*\*\*\*

**JLABS, Tuesday Morning, June 20, 2017**

Event: "Meet with... Novartis Venture Fund"

Date and Time: Tuesday, June 20, 2017 from 10:30 AM to 1:00 PM (PDT)

Agenda:

9:00 AM | Registration, Breakfast, and Networking

9:30 AM | Components of a collaboration agreement

10:00 AM | Panel Discussion: Implications of Components

11:00 AM | Q&A

11:30 AM | Program Close

\*Companies must have applied for a one-on-one meeting ahead of time and been approved. Applications are due May 19, 2017. Apply Here.

Location: JLABS @ SSF, 329 Oyster Point Blvd - 3rd Floor, South San Francisco, California

Ticket Information

Fees:

Presentation

\$25 | General Public

\$35 | Onsite

Includes presentation, Q&A, and lunch. All attendees must pay this fee, regardless of one-on-one meeting status. Pre-registration to attend the presentation, Q&A, and lunch will remain open until noon on June 20 (or sold out).

One-on-One Meeting

FREE | Application

FREE | Accepted Companies

Apply to meet one-on-one with representatives from Novartis Venture Fund. Your application will be reviewed and you will be notified of acceptance on Monday June 6, 2017. Acceptance of a one-on-one meeting is not guaranteed as all applications must be approved.

Event Details

Let's get more solutions to patients. The Johnson & Johnson Innovation, JLABS (JLABS) Meet with... Series helps life sciences entrepreneurs, as well as the academic community, connect with potential partners including corporate venture, VC's, Angels and other investment entities.

On June 20th Principal Christine Brennan and Life Sciences Investment and Operations Professional Giovanni Ferrara of the Novartis Venture Fund (NVF) team will be in attendance to give an overview presentation about the fund's key areas of interest and to meet 1-on-1 with companies that have been accepted after applying online.

Program Overview:

The Novartis Venture Fund founded in 1996, currently manages over \$750 Million in committed capital, and has investments in ~40 portfolio companies globally. NVF's strategy is to build a diverse portfolio of life science companies, across:

Biotechnology/biopharma

Medical device/diagnostics

Digital/eHealth

NVF is stage agnostic and engages in seed investments as well as later-stage investments, typically investing up to \$15 - \$20 million over the life of the company. In investing, NVF looks for unmet need and clinical impact, novel proprietary science and understanding of mechanism, management and board experience and capital efficiency.

Following the presentation, don't miss this opportunity to introduce yourself to the team during the networking lunch. And finally, for those companies who apply online and are approved, one-on-one meetings with Novartis Venture Fund will provide an intimate forum to discuss your company

Speaker Bios:

Christine Brennan | Principal, Novartis Venture Fund

Dr. Brennan joined the Novartis Venture Fund in November 2013. Prior to joining Novartis Venture Fund, Dr. Brennan spent 3 years at Vitae Pharmaceuticals as Chief Business Officer responsible for strategy & business development. Prior to Vitae, she spent 5 years at Novartis Institutes for BioMedical Research in Strategic Alliances, most recently as Executive Director and Head of Strategy & Operations. Prior to Novartis, she held positions in business development and marketing at the biopharmaceutical companies, EnVivo Pharmaceuticals (now FORUM

Pharmaceuticals), Biovail (now Valeant Pharmaceuticals) and Cogent Neuroscience. In addition, she was Director at Fidelity Biosciences Group (now F-Prime Capital Partners), a venture capital company. She received her Ph.D. in neuroscience from Dartmouth Medical School in 1995 and completed a postdoctoral fellowship at the National Institutes of Health in 1999.

Giovanni Ferrara | Life Sciences Investment and Operations Professional, Novartis Venture Fund